Cell Type Dependent Regulation of Neuronal Activity via SIRT1 in Depression

Dysregulation of glutamatergic and GABAergic signaling in certain brain regions is a well-established pathological hallmark of many central nervous system (CNS) disorders [1-3], with depression being a prime example [4, 5]. The central amygdala (CeA) has emerged as a critical region in governing psychiatric health. Specifically, increased excitatory output from glutamatergic neurons or functional deficits in GABAergic inhibitory neurons within the CeA have been consistently linked to depressive-like behaviors in animal models [6]. However, the upstream molecular mechanism that regulates the functional integrity of these distinct neuronal populations within the CeA remains unclear. Clarifying these pathways is therefore urgently needed, as it holds the key to identify novel therapeutic targets for restoring the fine balance between excitatory and inhibitory neurotransmitters that is essential for determining depressive behaviors. A recent study in Acta Physiologica titled “Cell type-specific loss of SIRT1 in central amygdala leads to depression-like behaviors by altering neuronal excitability in mice” [7], Wang and colleagues identified Sirtuin 1 (SIRT1), a nicotinamide adenine dinucleotide (NAD)+-dependent histone deacetylase, as a key molecular regulator governing the activity of CeA neurons, revealing a dual role that is cell-type dependent. SIRT1 has been previously identified as a key molecule in regulating negative emotion such as depression in animal models, positioning it as a potential therapeutic target for alleviating depression-related pathology [8]. However, given the functional heterogeneity of SIRT1 across different brain regions and cell types, the development of SIRT1-targeting interventions remains a critical challenge. Wang and colleagues previously demonstrated that SIRT1 in the CeA can mediate chronic pain-induced depression [9], suggesting that CeA SIRT1 might serve as a key molecule involved in the development of depression. Therefore, understanding how SIRT1 affects different CeA neuronal subtypes is essential for refining therapeutic strategies to restore neuronal balance in depression. The recent study by Wang and colleagues reveals that the function of SIRT1 in the CeA is highly cell-type dependent. Specifically, knocking down SIRT1 in CeA glutamatergic neurons directly increases their activity, leading to hyperexcitability and subsequent depressive-like behaviors. In contrast, knocking down SIRT1 in GABAergic neurons produces a dual effect: it not only reduces the inhibitory output of GABAergic neurons but also indirectly increases the activity of glutamatergic neurons. Together, these findings establish that the disruption of excitatory and inhibitory output within the CeA is a key mechanism underlying depression, highlighting SIRT1 as a cell type specific regulator of neuronal activity. Such findings provide a more precise clarification of treatment targeting SIRT1 (Figure 1). Critically, the authors also performed a functional rescue using optogenetic tools, by demonstrating that selectively inhibiting overactive CeA glutamatergic neurons alleviates depressive-like behaviors in SIRT1 deficiency mice. This finding suggests that increasing excitatory neuronal output is necessary for the onset of depression. Conversely, activating GABAergic neurons, which likely restores local inhibitory activity, can produce a potent antidepressant effect. Outcomes from these interventions strongly suggest that restoring the balance between excitatory and inhibitory elements within the CeA is sufficient to mitigate depression, providing a precise therapeutic target for developing future cell-type-specific interventions. Thus, SIRT1 can produce opposite effects depending on the specific neuronal cell type it acts upon, highlighting how the same molecular regulator can have contrasting roles in different neuronal populations. This study also provides a cellular-level framework for understanding the heterogeneity of depression, by precise genetic manipulations. It reveals that SIRT1 regulates neuronal activity through both cell-autonomous mechanisms and local microcircuits, specifically, the GABAergic neuronal control of glutamatergic neurons. Furthermore, the methodological rigor of using bidirectional optogenetic manipulations provided robust evidence to support a novel mechanism linking molecule (SIRT1), cellular populations (neuronal subtypes), function (excitatory/inhibitory output), and behavioral outcomes (depressive phenotypes). Collectively, this work not only elucidates the dual role of SIRT1 in the CeA but also demonstrates that the balance of excitatory and inhibitory output is a direct driver of depressive pathology. These findings provide a novel insight in deciphering the molecular and functional changes of neurons in depression and open new avenues for developing cell-type-specific therapeutic strategies. SIRT1 may regulate excitatory signaling through targets such as glutamatergic receptor genes (e.g., Grik3, Gria4, Grik1, and Grm1) [10], while influencing inhibitory signaling via GABA-related gene expression (e.g., Gabbr2, Gabra2) [10]. However, there are still unresolved questions. For example, how chronic stress signals such as pain transmitted to SIRT1 in specific CeA neuronal populations? Do differences in downstream targets correspond to distinct depressive symptoms? Building on these findings, future strategies should aim to precisely restore homeostasis of excitatory and inhibitory neurons by targeting specific neuronal subtypes within defined brain regions, such as the CeA, thereby enabling more effective and precise antidepressant therapies. This could be achieved through advanced approaches such as viral-mediated gene delivery, chemogenetics, or neuromodulation techniques. The authors declare no conflicts of interest. Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.